Business
Vanda Pharmaceuticals Announces Presentations at DDW 2023
WASHINGTON, May 4, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at Digestive Disease Week (DDW) 2023,
About this update from Vanda Pharmaceuticals Inc.
[{"type":"text","content":"WASHINGTON, May 4, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at Digestive Disease Week (DDW) 2023, to be held in Chicago, IL and online from May 6-9, 2023.\nThe following will be presented:\nMay 7, 2023\nPresentation Title: \"THE ROLE OF TENASCIN-X IN IDIOPATHIC GASTROPARESIS: WGS ANALYSIS\"Poster Number: Su1618Presenter: Dr. Sandra Paulina Smieszek, Head of GeneticsSession Type: Poster SessionSession Title: AGA Gastroparesis and Small Intestinal DysmotilitySession Time: 12:30 PM to 1:30 PM CDT\nPresentation Title: \"POOLED EFFICACY ANALYSIS OF TRADIPITANT IN IDIOPATHIC AND DIABETIC GASTROPARESIS STUDY VP-VLY-686-3301 AND VP-VLY-686-2301\" Poster Number: Su1632Presenter: Dr. Jesse L. Carlin, Clinical Project LeadSession Type: Poster SessionSession Title: AGA Gastroparesis and Small Intestinal DysmotilitySession Time: 12:30 PM to 1:30 PM CDT\nPresentation Title: \"EFFICACY ANALYSIS OF TRADIPITANT IN IDIOPATHIC AND DIABETIC GASTROPARESIS IN STUDY VP-VLY-686-3301\"Poster Number: Su1633Presenter: Dr. Jesse L. Carlin, Clinical Project LeadSession Type: Poster SessionSession Title: AGA Gastroparesis and Small Intestinal DysmotilitySession Time: 12:30 PM to 1:30 PM CDT\nPresentation Title: \"A BASELINE SEVERITY INFLATION ANALYSIS IN STUDY VP-VLY-686-3301 OF TRADIPITANT IN GASTROPARESIS\"Poster Number: Su1634Presenter: Dr. Jesse L. Carlin, Clinical Project LeadSession Type: Poster SessionSession Title: AGA Gastroparesis and Small Intestinal DysmotilitySession Time: 12:30 PM to 1:30 PM CDT\nFor more information on DDW 2023, please refer to https://ddw.org/.\nAbout Vanda Pharmaceuticals Inc.\nVanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.\nCorporate Contact:Kevin MoranSenior Vice President, Chief Financial Officer and Treasurer Vanda Pharmaceuticals [email protected]\nElizabeth Van EveryHead of Corporate AffairsVanda Pharmaceuticals [email protected] \n View original content:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-presentations-at-ddw-2023-301816683.html\nSOU...